The Cole Eye Institute Retina Summit took place on April 27, 2018.

Retina experts discuss recent clinical study results and their application to clinical practice; active clinical investigations of potential new therapies; applications of new imaging techniques; advances in surgical instrumentation; and the optimal management of retinal diseases.

Session Topics

  • Long-Term Treatment Outcomes in Exudative AMD – Rishi P. Singh, MD
  • Surgical Drug Delivery – Allen C. Ho, MD
  • Advances in the Diagnosis and Treatment of Polypoidal Choroidal
    Vasculopathy – Gregg T. Kokame, MD
  • Gene Therapy for AMD and Other Retinal Diseases – Allen C. Ho, MD
  • Geographic Atrophy: What Causes It and Can It Be Treated? – Daniel F. Martin, MD
  • Future Therapies for Neovascular AMD – Peter K. Kaiser, MD
  • PANEL: AMD Case Discussion – Peter K. Kaiser, MD


  • AMD

    Drs. Singh, Ho, Kokame, Martin & Kaiser
Target Audience

The Cole Eye Institute Retina Summit is for retina specialists, comprehensive ophthalmologists, retina fellows, and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treatments for retinal and vitreoretinal diseases.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
• Assess treatment strategies for retinal diseases
• Identify therapeutic options for the management of treatment-resistant retinal diseases
• Employ treatment protocols to optimize outcomes over the long term for patients with retinal disease
• Integrate imaging technologies into clinical practice for early detection, typing, and monitoring of retinal diseases
• Adopt best practices in surgery for patients with retinal disease
• Summarize recent clinical trial data for emerging and established therapies for retinal diseases

Method of Participation

Statements of credit will be awarded based on the participant’s attendance. A statement of credit will be available upon completion of an online evaluation/claimed credit form available at

Please claim your credit by July 1, 2019.

If you have questions about this CME activity, please contact AKH Inc. at


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by an independent medical education
grant from Regeneron Pharmaceuticals, Inc., Alcon Laboratories, Inc.,
Genentech, and Santen.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Faculty Disclosures

Netan Choudhry, MD, FRCSC, DABO

  • Consultant: Bayer, Allergan, Optos, Johnson & Johnson
  • Speakers Bureau: Topcon, Optos PLC, Allergan, Bayer
  • Contracted Research: Topcon, Bayer

Justis Ehlers, MD

  • Consultant: Alcon, Thrombogenics, Santen, Zeiss, Alimera, Leica, Genentech
  • Contracted Research: Alcon, Genentech, Regeneron

Allen C. Ho, MD

  • Consultant: Alcon, Genentech, Janssen, Regeneron, Regenix

Peter K. Kaiser, MD

  • Consultant: Alcon, Allergan, Allegro, Aerpio, Bausch and Lomb, Bayer, Benitec, Biogen Idec, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, Eyevensys, Ocunexus, Omeros, ONL, Regeneron, Novartis, Kanghong, Ophthotech, Ohr, Santen, SciFluor, Shire, Thrombogenics

Judy E. Kim, MD

  • Consultant: Genentech, Carl Zeiss, NotalVision, Alimera Sciences

Gregg T. Kokame, MD

  • Speakers Bureau: Regeneron, Bayer, Second Sight, Bausch and Lomb
  • Consultant: Genentech, Santen, Regeneron, Bayer, Bausch and Lomb, Zeiss, Ophthotech, Allergan
  • Contracted Research: Genentech, Regeneron

Daniel F. Martin, MD

  • Nothing to disclose

William F. Mieler, MD

  • Nothing to disclose

Rishi P. Singh, MD

  • Consultant: Genentech, Regeneron, Zeiss, Optos
  • Contracted Research: Apellis

Richard F. Spaide, MD

  • Consultant: Topcon, Boehringer Ingelheim
  • Royalty: Topcon Medical Systems, DORC

Sunil Srivastava, MD

  • Consultant: Santen, Bausch and Lomb, Allergan, Gilead, Regeneron, Psivida
  • Contracted Research: Santen, Psivida, Bausch and Lomb
  • Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose


Please answer the following pre-questions before moving on to the session presentations.

First Name*
Last Name*

According to outcomes data from the SEVEN-UP trial, which of the following were primary anatomic determinants of visual outcomes seven years after the initiation of intensive ranibizumab therapy for exudative age-related macular degeneration?

Macular atrophy progression and severity
Acute retinal necrosis
Discomfort and increased tears in the affected eye(s)
Retinal detachment (RD)

Suprachoroidal delivery of drug therapy:

May achieve drug delivery to the subretinal space and requires retinotomy
May achieve drug delivery to the subretinal space without retinotomy
Does not improve drug dosing consistency in the subretinal space
May only be used for corticosteroid therapy

Polypoidal choroidal vasculopathy is a variant of exudative macular degeneration and the aneurysmal subretinal neovascularization is located:

In the choroid
In the retina
In the subretinal space
Usually between Bruch’s membrane and under the RPE